Although immune system plays a key role in the pathogenesis of both endometriosis and ovarian cancer, its function is different. Therefore, we hypothesized, that selected immune parameters can serve as diagnostic markers of these two conditions. The aim of this study was to compare serum and peritoneal fluid concentrations of sHLA-G, IL-10 and TNF-alpha in women with selected ovarian pathologies: benign serous cysts, endometrioma and malignant tumors. Clinical significance of using them for diagnostic purposes in women with serous ovarian cysts, endometriosis, and ovarian cancer, which in the future may improve the early diagnosis of ovarian diseases.
The study included women treated surgically for benign serous ovarian cysts, ovarian endometrioma and serous ovarian adenocarcinomas. Peripheral blood and peritoneal fluid samples were obtained intraoperatively.
Patients with benign serous cysts, endometrioma and ovarian malignancies did not differ significantly in terms of their serum and peritoneal fluid concentrations of sHLA-G. Ovarian cancer patients presented with significantly higher median serum concentrations of IL-10 and TNF-alpha than other study subjects. Median concentrations of IL-10 and TNF-alpha in peritoneal fluid turned out to be the highest in ovarian cancer patients, followed by women with endometrioma and subjects with benign serous cysts. All these intergroup differences were statistically significant. Irrespective of the group, median concentrations of sHLA-G, IL-10 and TNF-alpha in peritoneal fluid were higher than serum levels of these markers.
Elevated serum and peritoneal fluid concentrations of IL-10 and TNF-alpha distinguish ovarian malignancies and endometriomas from benign serous ovarian cysts. In contrast to endometriosis, ovarian malignancies are characterized by elevated peritoneal fluid concentrations of IL-10 and TNF-alpha, elevated serum concentrations of IL-10 and low serum levels of TNF-alpha. Serum and peritoneal fluid concentrations of sHLA-G have no diagnostic value in differentiating between ovarian malignancies and endometriomas.
Ulukus M, Arici A. Immunology of endometriosis. Minerva Ginecol. 2005;57:237–48. PubMed
Aris A. Endometriosis-associated ovarian cancer: a ten-year cohort study of women living in the Estrie Region of Quebec, Canada. J Ovarian Res. 2010;3:1757–2215. CrossRef
Kobayashi H, Higashiura Y, Shigetomi H, Kajihara H. Pathogenesis of endometriosis: the role of initial infection and subsequent sterile inflammation (Review). Mol Med Rep. 2014;9:9–15. PubMed
Canis M, Donnez J, Guzick D, Halme JRock J, Schenken R, et al. Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil Steril. 1997;67:817–21. CrossRef
Singer G, Rebmann V, Chen YC, Liu HT, Ali SZ, Reinsberg J, et al. HLA-G is a potential tumor marker in malignant ascites. Clin Cancer Res. 2003;9:4460–4. PubMed
Mach P. The clinical significance of HLA-G in the context of gynecological cancer and conditions associated with pregnancy. Arch Perinatal Med. 2013;19:156–65.
Basta P, Gałązka K, Stasienko E, Dutsch-Wicherek M, Wicherek Ł. Analysis of B7H4 and HLA-G immunoreactivity within ovarian cancer relapse and its microenvironment according to the preceding applied chemotherapy. Curr Gynecol Oncol. 2011;9:9–17.
Matalliotakis IM, Athanassakis I, Goumenou AG, Neonaki MA, Koumantakis EE, Vassiliadis S, et al. The possible anti-inflammatory role of circulating human leukocyte antigen levels in women with endometriosis after treatment with danazol and leuprorelin acetate depot. Mediators Inflamm. 2001;10:75–80. CrossRefPubMedPubMedCentral
Podgaec S, Dias Junior JA, Chapron C, Oliveira RM, Baracat EC, Abrao MS. Th1 and Th2 ummune responses related to pelvic endometriosis. Rev Assoc Med Bras. 1992;56:92–8. CrossRef
Galo S, Zubor P, Szunyogh N, Kajo K, Machalekova K, Biringer K, et al. TNF-alpha serum levels in women with endometriosis: prospective clinical study. Ceska Gynekol. 2005;70:286–90. PubMed
Berek JS, Bast Jr RC, Lichtenstein A, Hacker NF, Spina CA, Lagasse LD, et al. Lymphocyte cytotoxicity in the peritoneal cavity and blood of patients with ovarian cancer. Obstet Gynecol. 1984;64:708–14. PubMed
Mustea A, Konsgen D, Braicu EI, Pirvulescu C, Sun P, Sofroni D, et al. Expression of IL-10 in patients with ovarian carcinoma. Anticancer Res. 2006;26:1715–8. PubMed
Cassatella MA, Meda L, Bonora S, Ceska M, Constantin G. Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by lipopolysaccharide. J Exp Med. 1993;178:2207–11. CrossRefPubMed
Sebti Y, Le Maux A, Gros F, De Guibert S, Pangault C, Rouas-Freiss N, et al. Soluble HLA-G molecules are increased in lymphoproliferative disorders. Br J Hematol. 2007;138:202–12. CrossRef
- Serum and peritoneal fluid concentrations of soluble human leukocyte antigen, tumor necrosis factor alpha and interleukin 10 in patients with selected ovarian pathologies
- BioMed Central
Neu im Fachgebiet Gynäkologie und Geburtshilfe
Meistgelesene Bücher aus dem Fachgebiet
Mail Icon II